ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it will present at the Emerging Growth Conference 86 on September 25, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investme ...

Core Viewpoint - Vivani Medical, Inc. is preparing to present its innovative drug implant technology at the H.C. Wainwright 27th Annual Global Investment Conference, focusing on improving medication adherence and patient outcomes in chronic disease management [1][3]. Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company specializing in miniature, ultra long-acting drug implants [1][3]. - The company utilizes its proprietary NanoPortal™ technology to develop biopharmaceutical implants that deliver drug molecules steadily over extended periods [3]. - Medication non-adherence affects approximately 50% of patients, highlighting the need for innovative solutions [3]. Product Pipeline - The priority product candidate is NPM-139, a miniature, six-month, subdermal GLP-1 (semaglutide) implant aimed at chronic weight management in obese or overweight individuals [3]. - NPM-139 has the potential for once-yearly dosing, which could significantly enhance patient compliance [3]. - Other products in development include NPM-115 (exenatide implant) for chronic weight management and NPM-119 (exenatide implant) for type-2 diabetes treatment [3]. Upcoming Presentation Details - CEO Adam Mendelsohn will present on September 10, 2025, at the Lotte New York Palace Hotel, focusing on the company's innovative drug implant technology [1]. - The presentation is part of the H.C. Wainwright 27th Annual Global Investment Conference, which runs from September 8-10, 2025 [1].

Core Insights - Vivani Medical, Inc. has appointed Anthony Baldor as Chief Financial Officer, succeeding Brigid A. Makes, who is retiring to focus on other commitments [1][3] - Baldor has over 20 years of financial management experience in the biotechnology sector, with a strong background in fundraising and corporate strategy [2] - The CEO of Vivani, Adam Mendelsohn, expressed confidence in Baldor's expertise to advance the company's pipeline and operations during a critical period [3] Company Overview - Vivani Medical develops miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform, aimed at improving medication adherence and patient tolerance [4] - The lead program, NPM-115, is a six-month GLP-1 implant for chronic weight management, with additional products in the pipeline, including NPM-139 and NPM-119, targeting similar therapeutic areas [4] - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [4]